VistaGen Therapeutics Inc
Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an od… Read more
VistaGen Therapeutics Inc (VTGN) - Total Liabilities
Latest total liabilities as of December 2025: $14.14 Million USD
Based on the latest financial reports, VistaGen Therapeutics Inc (VTGN) has total liabilities worth $14.14 Million USD as of December 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
VistaGen Therapeutics Inc - Total Liabilities Trend (2008–2025)
This chart illustrates how VistaGen Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
VistaGen Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of VistaGen Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Singsongholdin
KO:006880
|
Korea | ₩160.72 Billion |
|
Strategic Resources Inc
PINK:SCCFF
|
USA | $14.92 Million |
|
Janover Inc. Common Stock
NASDAQ:JNVR
|
USA | $1.31 Million |
|
Star Comgistic Capital Co Ltd
TW:4930
|
Taiwan | NT$4.89 Billion |
|
Pakka Limited
NSE:PAKKA
|
India | ₹3.77 Billion |
|
Min Aik Precision Industrial Co Ltd
TW:4545
|
Taiwan | NT$1.23 Billion |
|
Southern Steel Bhd
KLSE:5665
|
Malaysia | RM526.39 Million |
Liability Composition Analysis (2008–2025)
This chart breaks down VistaGen Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.67 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.28 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.22 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how VistaGen Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for VistaGen Therapeutics Inc (2008–2025)
The table below shows the annual total liabilities of VistaGen Therapeutics Inc from 2008 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | $13.95 Million | +48.94% |
| 2024-03-31 | $9.37 Million | +3.97% |
| 2023-03-31 | $9.01 Million | -9.26% |
| 2022-03-31 | $9.93 Million | -39.10% |
| 2021-03-31 | $16.30 Million | +41.74% |
| 2020-03-31 | $11.50 Million | +65.81% |
| 2019-03-31 | $6.94 Million | +59.03% |
| 2018-03-31 | $4.36 Million | +40.86% |
| 2017-03-31 | $3.10 Million | -21.95% |
| 2016-03-31 | $3.97 Million | -80.94% |
| 2015-03-31 | $20.81 Million | +59.32% |
| 2014-03-31 | $13.06 Million | -2.79% |
| 2013-03-31 | $13.44 Million | +122.22% |
| 2012-03-31 | $6.05 Million | +188875.00% |
| 2011-03-31 | $3.20K | +113.33% |
| 2010-03-31 | $1.50K | -44.15% |
| 2009-03-31 | $2.69K | +1019.17% |
| 2008-03-31 | $240.00 | -- |